Advertisement

Topics

Novartis reports positive interim Phase III data for Zolgensma gene therapy candidate in SMA type 1 https://firstwordpharma.com/node/1635611?tsid=28®ion_id=6 …

18:40 EDT 16 Apr 2019 | FirstWord Pharma

Novartis reports positive interim Phase III data for Zolgensma gene therapy candidate in SMA type 1 https://firstwordpharma.com/node/1635611?tsid=28&region_id=6 …

Original Article: Novartis reports positive interim Phase III data for Zolgensma gene therapy candidate in SMA type 1 https://firstwordpharma.com/node/1635611?tsid=28®ion_id=6 …

NEXT ARTICLE

More From BioPortfolio on "Novartis reports positive interim Phase III data for Zolgensma gene therapy candidate in SMA type 1 https://firstwordpharma.com/node/1635611?tsid=28®ion_id=6 …"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Gene Therapy
Gene therapy is the use of DNA as a pharmaceutical agent to treat disease. It derives its name from the idea that DNA can be used to supplement or alter genes within an individual's cells as a therapy to treat disease. The most common form of gene th...